NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

EWTX

Edgewise Therapeutics Inc

Jul 03 • 04:00PM ET

13.03

Dollar change +0.02
Percentage change 0.15	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY SRPT CRSP RARE BMRN PTCT QURE SGMO VYGR PRQR

| Held by: VTI IWM VXF IWO IBB VTWO SCHA XPH IHE DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.55	Insider Own	26.71%	Shs Outstand	95.21M	Perf Week	-0.23%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-2.01	Insider Trans	3.40%	Shs Float	77.10M	Perf Month	-12.20%
Enterprise Value	938.93M	PEG	-	EPS next Q	-0.41	Inst Own	74.46%	Short Float	16.25%	Perf Quarter	-16.04%
Income	-146.09M	P/S	-	EPS this Y	-20.45%	Inst Trans	11.22%	Short Ratio	9.21	Perf Half Y	-51.84%
Sales	0.00M	P/B	2.89	EPS next Y	-15.37%	ROA	-28.98%	Short Interest	12.53M	Perf YTD	-51.20%
Book/sh	4.51	P/C	3.14	EPS next 5Y	-10.76%	ROE	-30.29%	52W High	38.12 -65.82%	Perf Year	-32.77%
Cash/sh	4.15	P/FCF	-	EPS past 3/5Y	-18.74% -49.00%	ROIC	-33.72%	52W Low	10.60 22.92%	Perf 3Y	67.70%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.40% 4.85%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-0.86%	Oper. Margin	-	ATR (14)	0.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	20.99	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.54	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	20.99	EPS Q/Q	-31.65%	SMA20	-9.08%	Beta	0.26	Target Price	38.45
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-11.32%	Rel Volume	0.27	Prev Close	13.01
Employees	110	LT Debt/Eq	0.01	Earnings	May 08 BMO	SMA200	-45.86%	Avg Volume	1.36M	Price	13.03
IPO	Mar 26, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.44% -	Trades		Volume	361,183	Change	0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Initiated	H.C. Wainwright	Buy	$42
Apr-30-25	Initiated	Guggenheim	Buy	$41
Apr-02-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$14
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Jan-22-25	Initiated	Stifel	Hold	$30
Nov-22-24	Initiated	Evercore ISI	Outperform	$45
Mar-07-24	Initiated	Piper Sandler	Overweight	$48
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell	$5
Apr-13-22	Initiated	RBC Capital Mkts	Outperform	$31
Jan-28-22	Initiated	Goldman	Neutral	$11

Show Previous Ratings

Jul-04-25 02:43AM	Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment (Insider Monkey)
Jun-28-25 09:25AM	Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush (TipRanks)
Jun-26-25 06:00AM	Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies (PR Newswire) -8.86%
Jun-03-25 08:00AM	Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference (PR Newswire)
May-19-25 12:00PM	All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy (Zacks)
05:55PM	Loading…
May-16-25 05:55PM	Treehouse Foods, GeneDx Holdings See Activist Action (Barrons.com)
May-14-25 09:55AM	Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? (Zacks)
08:00AM	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 (PR Newswire)
May-08-25 08:00AM	Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
May-05-25 07:57AM	Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
May-02-25 07:07PM	Why Edgewise Therapeutics Stock Popped This Week (Motley Fool)
Apr-25-25 04:31PM	Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey) +5.66%
Apr-15-25 06:00AM	Bristol Myers stumbles in bid to widen heart drugs use (BioPharma Dive) +5.60%
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -7.44%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks) +8.79%
09:33PM	Loading…
Apr-08-25 09:33PM	Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey)
Apr-07-25 12:17PM	EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data (Zacks)
Apr-05-25 05:29PM	Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Apr-03-25 02:16PM	Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial (GuruFocus.com) -12.50%
Apr-02-25 04:54PM	Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (Seeking Alpha) -22.90%
04:36PM	Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged (Investor's Business Daily)
03:02PM	Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' (Investopedia)
06:22AM	Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock (PR Newswire)
06:00AM	Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) (PR Newswire)
Mar-26-25 04:45PM	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time (PR Newswire) +5.30%
Mar-11-25 08:00AM	Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference (Business Wire)
Mar-04-25 08:00AM	Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 (Business Wire)
Mar-03-25 08:00AM	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Feb-19-25 10:46AM	Should You Invest in Edgewise Therapeutics (EWTX)? (Insider Monkey)
Jan-23-25 01:37AM	Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? (Insider Monkey)
08:00AM	Loading…
Jan-22-25 08:00AM	Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development (Business Wire)
Jan-13-25 08:00AM	Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 (Business Wire)
Jan-07-25 08:00AM	Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 (Business Wire)
Dec-16-24 11:56AM	Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease (Benzinga) +18.36%
07:02AM	Edgewise weighs fast approval path for muscular dystrophy drug (BioPharma Dive)
06:00AM	Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) (Business Wire)
Dec-05-24 02:32PM	Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research (Business Wire)
Nov-26-24 06:00AM	Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 (Business Wire)
Nov-07-24 08:00AM	Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Oct-07-24 05:37PM	Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now (Insider Monkey)
Oct-01-24 08:00AM	Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society (Business Wire)
Sep-20-24 07:28AM	Novo sinks on obesity drug results; Sanofi reveals anticipated MS data (BioPharma Dive)
04:52AM	Edgewises EDG-7500 shows benefit in two obstructive HCM trials (Clinical Trials Arena)
Sep-19-24 04:08PM	How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease (Investor's Business Daily) +54.69%
12:55PM	Why Edgewise Therapeutics Stock Is Up 50% on Thursday (Motley Fool)
09:22AM	Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip (Investor's Business Daily)
07:00AM	Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) (Business Wire)
Sep-17-24 04:01PM	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time (Business Wire) +7.21% +5.50%
Aug-08-24 08:00AM	Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Jul-30-24 12:25PM	7 Small-Cap Stocks to Buy for Large-Scale Gains (InvestorPlace) -5.49%
Jul-21-24 09:00AM	Dont Be Scared of Heights: J.P. Morgan Suggests 2 Stocks to Buy (TipRanks)
Jul-17-24 12:00PM	Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy (Zacks)
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
May-10-24 01:38PM	Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results (GuruFocus.com) -8.35%
08:00AM	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 (Business Wire)
05:32AM	Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating (MT Newswires)
May-09-24 01:53PM	EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
May-07-24 08:00AM	Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors (Business Wire)
05:02AM	Edgewise Therapeutics doses first subject in HCM drug trial (Clinical Trials Arena)
May-06-24 09:01AM	Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial (MT Newswires)
08:00AM	Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) (Business Wire)
Apr-23-24 09:34AM	Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU (MT Newswires)
08:00AM	Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies (Business Wire)
Apr-15-24 04:05PM	Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) (Business Wire)
Mar-28-24 08:00AM	Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session (Business Wire)
Mar-27-24 08:00AM	Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 (Business Wire)
Mar-05-24 08:00AM	Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 (Business Wire)
Feb-28-24 08:00AM	Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference (Business Wire)
Feb-26-24 09:55AM	Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know (Zacks)
Feb-22-24 08:00AM	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (Business Wire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-13-24 08:00AM	Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) (Business Wire)
Feb-11-24 02:55PM	Insider Favorites: 7 Stocks with Bullish Buying Signals (InvestorPlace)
Feb-09-24 09:55AM	Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High? (Zacks)
Jan-25-24 10:04PM	Edgewise Therapeutics Inc CFO R Carruthers Sells 90,000 Shares (GuruFocus.com) +5.02%
Jan-24-24 09:55AM	Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet (Zacks)
Jan-22-24 02:06PM	Edgewise (EWTX) Rallies 35% on Issue of New Common Stock (Zacks) +19.25%
Jan-19-24 08:37AM	Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock (Business Wire) +34.57%
Jan-16-24 09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool) -6.20%
Jan-09-24 08:39AM	Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-29-23 11:02PM	Edgewise Therapeutics Inc Director Jonathan Fox Acquires 10,857 Shares (GuruFocus.com)
Dec-19-23 08:00AM	Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 (Business Wire) +16.10%
Dec-18-23 08:00AM	Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community (Business Wire) +8.23%
Nov-30-23 08:00AM	Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA (Business Wire)
Nov-28-23 07:29AM	Speculators Watch List: 7 Stocks Ripe for a Short-Squeeze Windfall (InvestorPlace)
Nov-09-23 09:41AM	Edgewise Therapeutics Inc (EWTX) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.29%
08:00AM	Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
Nov-08-23 08:00AM	Edgewise Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Nov-01-23 08:00AM	Edgewise to Present Data on EDG-7500 at the American Heart Associations Scientific Sessions 2023 (Business Wire)
Oct-26-23 08:00AM	Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne) (Business Wire) -6.69%
Oct-10-23 09:55AM	Wall Street Analysts See a 310.1% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High? (Zacks) +6.84%
Sep-27-23 08:00AM	Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society (Business Wire)
Sep-26-23 08:00AM	Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker) (Business Wire)
Sep-14-23 08:00AM	Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction (Business Wire) +5.65%
Sep-05-23 09:55AM	Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet (Zacks)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
Aug-16-23 09:55AM	Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to Trade (Zacks)
Aug-10-23 08:00AM	Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Russell Alan J	Chief Scientific Officer	May 01 '25	Option Exercise	0.00	5,209	0	20,072	May 07 09:10 PM
Russell Alan J	Chief Scientific Officer	May 02 '25	Sale	16.45	1,551	25,520	18,521	May 07 09:10 PM
MOORE JOHN R	General Counsel	May 01 '25	Option Exercise	0.00	5,209	0	8,461	May 07 09:10 PM
MOORE JOHN R	General Counsel	May 02 '25	Sale	16.45	1,930	31,757	6,531	May 07 09:10 PM
KOCH KEVIN	President and CEO	May 01 '25	Option Exercise	0.00	10,417	0	24,895	May 07 09:10 PM
KOCH KEVIN	President and CEO	May 02 '25	Sale	16.45	4,276	70,358	20,619	May 07 09:10 PM
Donovan Joanne M.	CMO	May 01 '25	Option Exercise	0.00	10,417	0	26,775	May 07 09:09 PM
Donovan Joanne M.	CMO	May 02 '25	Sale	16.45	5,187	85,348	21,588	May 07 09:09 PM
Derakhshan Behrad	Chief Business Officer	May 01 '25	Option Exercise	0.00	5,209	0	22,046	May 07 09:09 PM
Derakhshan Behrad	Chief Business Officer	May 02 '25	Sale	16.45	1,691	27,824	20,355	May 07 09:09 PM
Carruthers R Michael	Chief Financial Officer	May 01 '25	Option Exercise	0.00	5,209	0	82,328	May 07 09:08 PM
Carruthers R Michael	Chief Financial Officer	May 02 '25	Sale	16.45	1,314	21,621	81,014	May 07 09:08 PM
Thompson Peter A.	Director	Apr 03 '25	Buy	20.13	496,771	10,000,000	14,809,075	Apr 04 07:42 PM
ORBIMED ADVISORS LLC	Director	Apr 03 '25	Buy	20.13	496,771	10,000,000	14,809,075	Apr 04 07:33 PM
Russell Alan J	Chief Scientific Officer	Mar 07 '25	Option Exercise	0.18	200	36	15,063	Mar 11 04:33 PM
Russell Alan J	Chief Scientific Officer	Mar 07 '25	Sale	30.02	200	6,004	14,863	Mar 11 04:33 PM
KOCH KEVIN	President and CEO	Mar 07 '25	Option Exercise	0.18	100	18	14,578	Mar 11 04:32 PM
KOCH KEVIN	President and CEO	Mar 07 '25	Sale	30.00	100	3,000	14,478	Mar 11 04:32 PM
Russell Alan J	Chief Scientific Officer	Feb 05 '25	Option Exercise	0.18	8,015	1,443	22,878	Feb 07 04:38 PM
Russell Alan J	Chief Scientific Officer	Feb 06 '25	Option Exercise	0.18	1,200	216	16,063	Feb 07 04:38 PM
Russell Alan J	Chief Scientific Officer	Feb 05 '25	Sale	30.02	8,015	240,623	14,863	Feb 07 04:38 PM
Russell Alan J	Chief Scientific Officer	Feb 06 '25	Sale	30.13	1,200	36,153	14,863	Feb 07 04:38 PM
KOCH KEVIN	President and CEO	Feb 06 '25	Option Exercise	13.11	900	11,799	15,378	Feb 07 04:38 PM
KOCH KEVIN	President and CEO	Feb 05 '25	Option Exercise	0.18	8,636	1,554	23,114	Feb 07 04:38 PM
KOCH KEVIN	President and CEO	Feb 05 '25	Sale	30.03	8,636	259,298	14,478	Feb 07 04:38 PM
KOCH KEVIN	President and CEO	Feb 06 '25	Sale	31.13	900	28,018	14,478	Feb 07 04:38 PM
Derakhshan Behrad	Chief Business Officer	Feb 05 '25	Option Exercise	1.93	10,000	19,300	26,837	Feb 07 04:37 PM
Derakhshan Behrad	Chief Business Officer	Feb 05 '25	Sale	30.03	10,000	300,300	16,837	Feb 07 04:37 PM
KEVIN KOCH	Director	Feb 05 '25	Proposed Sale	29.50	51,181	1,509,840		Feb 05 04:20 PM
ALAN J RUSSELL	Director	Feb 05 '25	Proposed Sale	29.50	100,000	2,950,000		Feb 05 04:19 PM
Behrad Derakhshan	Officer	Feb 05 '25	Proposed Sale	29.80	40,000	1,192,000		Feb 05 04:09 PM
Donovan Joanne M.	CMO	Jan 28 '25	Option Exercise	7.08	25,000	177,000	41,358	Jan 30 04:05 PM
Donovan Joanne M.	CMO	Jan 28 '25	Sale	27.63	25,000	690,658	16,358	Jan 30 04:05 PM
JOANNE DONOVAN	Officer	Jan 28 '25	Proposed Sale	27.85	25,000	696,250		Jan 28 04:18 PM
Russell Alan J	Chief Scientific Officer	Dec 30 '24	Option Exercise	0.18	100,000	18,000	114,863	Dec 31 05:13 PM
Russell Alan J	Chief Scientific Officer	Dec 30 '24	Sale	27.37	100,000	2,737,470	14,863	Dec 31 05:13 PM
ALAN J RUSSELL	Director	Dec 30 '24	Proposed Sale	28.74	100,000	2,874,000		Dec 30 04:10 PM
Semigran Marc	Chief Development Officer	Dec 24 '24	Option Exercise	8.94	29,709	265,598	36,425	Dec 27 04:30 PM
Semigran Marc	Chief Development Officer	Dec 24 '24	Sale	29.69	29,709	881,915	6,716	Dec 27 04:30 PM
MARC J SEMIGRAN	Officer	Dec 24 '24	Proposed Sale	29.98	50,000	1,499,000		Dec 26 08:15 AM
Carruthers R Michael	Chief Financial Officer	Oct 11 '24	Option Exercise	0.71	70,000	49,700	76,904	Oct 16 04:23 PM
Russell Alan J	Chief Scientific Officer	Sep 20 '24	Option Exercise	0.18	75,000	13,500	87,719	Sep 24 08:25 PM
Russell Alan J	Chief Scientific Officer	Sep 20 '24	Sale	28.27	75,000	2,120,101	12,719	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 20 '24	Option Exercise	0.71	50,000	35,500	53,252	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 23 '24	Option Exercise	0.71	20,922	14,855	24,174	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 20 '24	Sale	28.37	50,000	1,418,510	3,252	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 23 '24	Sale	27.63	20,922	578,064	3,252	Sep 24 08:25 PM
Donovan Joanne M.	CMO	Sep 20 '24	Sale	28.29	7,162	202,603	14,538	Sep 24 08:24 PM
Derakhshan Behrad	Chief Business Officer	Sep 20 '24	Option Exercise	1.93	42,068	81,191	57,189	Sep 24 08:24 PM
Derakhshan Behrad	Chief Business Officer	Sep 20 '24	Sale	29.03	42,068	1,221,133	15,121	Sep 24 08:24 PM
Carruthers R Michael	Chief Financial Officer	Sep 20 '24	Option Exercise	1.93	96,068	185,411	81,996	Sep 24 08:22 PM
Carruthers R Michael	Chief Financial Officer	Sep 20 '24	Sale	28.57	125,092	3,573,980	6,904	Sep 24 08:22 PM
JOHN R MOORE	Officer	Sep 23 '24	Proposed Sale	27.63	20,922	578,064		Sep 23 04:13 PM
JOANNE DONOVAN	Officer	Sep 20 '24	Proposed Sale	28.29	7,162	202,603		Sep 20 05:37 PM
Behrad Derakhshan	Officer	Sep 20 '24	Proposed Sale	29.50	50,000	1,475,000		Sep 20 04:46 PM
ALAN J RUSSELL	Officer	Sep 20 '24	Proposed Sale	28.27	75,000	2,120,100		Sep 20 04:29 PM
ROBERT MICHAEL CARRUTHERS	Officer	Sep 20 '24	Proposed Sale	28.57	125,092	3,573,980		Sep 20 04:11 PM
JOHN R MOORE	Officer	Sep 20 '24	Proposed Sale	28.37	50,000	1,418,510		Sep 20 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EWTX

Edgewise Therapeutics Inc

Upgrade your FINVIZ experience